Copyright ©The Author(s) 2024.
World J Gastroenterol. Feb 28, 2024; 30(8): 833-842
Published online Feb 28, 2024. doi: 10.3748/wjg.v30.i8.833
Table 1 Characteristics of included randomized controlled trials
Patient population
Study design
Fecal donor
Sample size
Duration in wk
Craven et al[17], 2020Adults, NAFLDBiopsy, fibroscan, MRIDouble-blind, parallel, RCT3 donors, healthy, BMI < 25 kg/m2Treatment: Allogenic FMT1524HOMA-IR, hepatic PDFF, small intestine permeability, NEFA, cholesterol, HDL-C, LDL-C, triglycerides, glucose, BMI, weight, waist-to-hip ratio
Control: Autologous FMT6
FMT: Duodenal infusion
Witjes et al[18], 2020Adults, NAFLDUltrasoundDouble-blind, parallel, RCT3 donors, healthy, BMI < 25 kg/m2, 8-weekly veganTreatment: Allogenic FMT1024Histological change (NAS score, necro inflammation score, fibrosis score, steatosis score), intestinal microbiota composition, plasma metabolites, cholesterol, HDL-C, LDL-C, triglycerides, glucose, ALT, AST, monocytes
Control: Autologous FMT11
FMT: Duodenal infusion
Xue et al[19], 2022Adults, NAFLDFibroscanOpen-label, parallel, RCTHealthy undergraduate donorsTreatment: Allogenic FMT474ALT, AST, cholesterol, HDL-C, LDL-C, triglycerides, total bilirubin, Albumin, hepatic fat attenuation, changes in the gut microbiota, HOMA-IR, BMI
Control: Oral probiotics28
FMT: Colonic infusion